Skip to content
A7746Assembly2023-2024 SessionSame asS9890

Study New Opioids in Overdoses

Official title

“Directs the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state”

Sponsor Brian MaherAD-101+2 co-sponsorsAffects Health
Status
In Assembly Committee
Health
Impact
5/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill directs the health commissioner to study and report on new or unidentified opioids in overdose patients to improve treatment protocols.

Why it matters

  1. The bill seeks to uncover hidden dangers in the opioid crisis by systematically testing overdose patients for new, uncommon, or unidentified opioids. helping health professionals understand what substances are actually causing overdoses, which is crucial as synthetic and novel opioids continue to appear.

  2. The study maintains strict privacy protections for patients, explicitly barring test results from being used by law enforcement, child welfare, or probation/parole agencies. , which may encourage participation and help build trust among vulnerable populations.

  3. By requiring the use of advanced laboratory techniques to identify a wide range of substances, including combinations and adulterants like xylazine. , the bill aims to inform more precise and effective medical responses—recognizing that standard treatments like Narcan may not always work.

  4. The findings will directly influence emergency room and statewide overdose treatment protocols, ensuring that hospitals, addiction treatment centers, and policymakers have up-to-date, evidence-based recommendations. potentially saving lives by adapting to evolving drug trends.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Study New Opioids in Overdoses

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Brian Maher

Assembly Member · Assembly District 101

History

  1. Held for consideration in health
  2. Referred to health
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S9890Senate

Study New Opioid Overdose Drugs

In Senate Committee · Rules · Sponsor Robert Rolison

Impact 6 · Moderate0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

7746

2023-2024 Regular Sessions

IN ASSEMBLY

June 6, 2023

Introduced by M. of A. MAHER -- read once and referred to the Committee on Health

AN ACT directing the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state for the purpose of establishing more efficient overdose medical treatment protocols

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "identify dangerous drugs act (IDDA)".

§ 2. The opioid settlement fund advisory board, established pursuant to section 25.18 of the mental hygiene law, shall direct the commissioner of health to conduct a study of 250 random urine samples collected anonymously throughout the state of New York. Such samples shall: (i) represent each county in the state; (ii) be provided in accordance with HIPAA laws and regulations; and (iii) be identified by emergency room hospital physicians as having been generated from patients who, at the time of collection, were experiencing moderate to severe medical symptoms diagnosed as being directly related to an overdose associated from the use of an illicit unidentified opioid/opiate substance and/or combination of substances. Such urine samples shall:

(a) only be collected from patients diagnosed by an emergency room physician as experiencing moderate or severe overdose symptoms most likely related to opiate/opioid patient use;

(b) be collected by designated trained medical staff, including nurses, physicians, and physician assistants;

(c) be collected in tandem with the written and verbal consent of the patient and follow all designated HIPAA laws and regulations, including but not limited to identifying samples only by number on a form supplied to the hospital by the department of health. Such written consent shall

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD11513-01-3

be knowing and willful. The patient shall be verbally read conditions and forms by medical staff identified above and shall sign a document supplied by the department of health. Patients shall verbalize consent to the medical staff collecting the sample, as identified above, and shall be assessed by such staff as having full mental capacity as to consent to a legal document;

(d) be collected from a patient identified by the treating physician as experiencing current moderate to severe opiate/opioid overdose symptoms which may not have responded to emergency Narcan administration or the patient may be experiencing unusual or severe symptoms that the physician believes is related to opiate/opioid use, possibly in combination with other drugs. The treating physician must, in good faith, believe the patient is experiencing moderate to severe opiate/opioid related symptoms at the time the sample is collected and that such symptoms are from the use of illicit or non-prescribed medication or unintended use of prescribed medication in combination with an illicit drug.

§ 3. The samples collected pursuant to section two of this act shall be obtained only for the purpose of the study commissioned pursuant to section two of this act and shall not be accessed or reported for any other purpose including, but not limited to: use by law enforcement or the office of children and family services; consideration of probation or parole; or inclusion in the medical history of the patient. The study shall be conducted in good faith by all participating hospital staff and for the sole purpose of obtaining knowledge and information related to illicit opiate/opioid substance use.

§ 4. All samples collected, obtained, stored, and transported by physicians and emergency room staff should follow protocols established by the department of health. Such samples shall be sent to one designated laboratory with access to advanced chromatographic techniques, specifically liquid chromatography-tandem mass spectrometry (LC-MS-MS) and gas chromatography-mass spectrometry (GC-MS) to identify and measure a broad range of compounds, including new or unusual opiate analogs, xylazine or unidentified opiate/opioid compounds, combinations of illicit substances, and prescription medications.

§ 5. The study findings, data, results, treatment recommendations and suggested emergency room protocols shall be compiled into a report published by the commissioner of health which shall include recommended statewide treatment protocols and procedures. Such protocols and procedures shall take into consideration that the use of Narcan on patients with opiate/opioid overdose symptoms may not be sufficient for combatting a medical overdose emergency in a patient experiencing symptoms from new or unusual opiate analogs, xylazine or unidentified opiate/opioid compounds, commonly used combinations of illicit substances, or the unintended use of prescribed medication as found in the samples.

§ 6. Within one year from the effective date of this act, the commissioner of health shall submit the report required pursuant to section five of this act to the governor, the temporary president of the senate, the minority leader of the senate, the speaker of the assembly, the minority leader of the assembly, and the chairs and ranking members of the senate and assembly committees on health and shall post such report on the department of health's website. All hospitals and addiction treatment facilities shall be granted access to the report in a timely manner.

§ 7. The commissioner of health shall be authorized to promulgate rules and regulations to implement the provisions of this act.

§ 8. This act shall take effect immediately and shall expire and shall be deemed repealed thirty days after the delivery of the report to the governor and the legislature as provided for in section six of this act; provided that the commissioner of health shall notify the legislative bill drafting commission upon the occurrence of the delivery of the report provided for in section six of this act in order that the commission may maintain an accurate and timely effective data base of the official text of the laws of the state of New York in furtherance of effectuating the provisions of section 44 of the legislative law and section 70-b of the public officers law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.